There is an increasing incidence of revision for periprosthetic joint infection. The addition of vancomycin to beta-lactam antimicrobial prophylaxis in joint arthroplasty may reduce surgical site infections, however, the efficacy and safety have not been established.

This was a multicenter, double-blind, superiority, placebo-controlled trial. We randomized 4239 adult patients undergoing joint arthroplasty surgery to receive 1.5g vancomycin or normal saline placebo, in addition to standard cefazolin antimicrobial prophylaxis. The primary outcome was surgical site infection at 90-days from index surgery. Perioperative carriage of Staphylococcus species was also assessed.

In the 4113 patients included in the modified intention-to-treat population, surgical site infections occurred in 72/2069 (3.5%) in the placebo group and 91/2044 (4. 5%) in the vancomycin group (risk ratio 1.28; 95% confidence interval 0.94 to 1.73; p value 0.11). No difference was observed between the two groups for primary hip arthroplasty procedures. A higher proportion of infections occurred in knee arthroplasty patients in the vancomycin group (63/1109 [4.7%]) compared with the placebo group (42/1124 [3.7%]; risk ratio 1.52; 95% confidence interval 1.04 to 2.23; p value 0.031). Hypersensitivity reactions occurred in 11 (0.5%) patients in the placebo group and 24 (1.2%) in the vancomycin group (risk ratio 2.20; 95% confidence interval 1.08, 4.49) and acute kidney injury in 74 (3.7%) patients in the placebo group and 42 (2.1%) in the vancomycin group (risk ratio 0.57; 95% confidence interval 0.39, 0.83). Perioperative Staphylococcus aureus carriage was detected in 1089/3748 (29.1%) of patients.

This is the first randomized controlled trial examining the addition of a glycopeptide antimicrobial to standard beta-lactam surgical antimicrobial prophylaxis in joint arthroplasty. The addition of vancomycin to standard cefazolin prophylaxis was not superior to placebo for the prevention of surgical site infections in hip and knee arthroplasty surgery.

Introduction/Aims

The Exeter Stem can be used with metal femoral head that are made of either cobalt chrome, or stainless steel. The aim of this study was to compare the rates of revision of these two metal femoral head types when used with this femoral component.

Total Hip Arthroplasty (THA) is a successful operation for the management of end stage hip osteoarthritis (OA) but long term success is limited by wear of the polyethylene bearing surface. The aim of this study was to compare the rate of revision at 15 years in patients <55 who had a THA for OA, and received either cross-linked (XLPE) or conventional non cross-linked polyethylene (non-XLPE).

The study population was all patients with primary THAs undertaken for OA from 1999 to 31 December 2016. Outcomes were determined for all procedures, comparing THA performed with non-XLPE and XLPE and including the effect of age, sex, and reason for revision. The principal outcome measure was time to first revision using Kaplan-Meier estimates of survivorship.

There were 17,869 procedures recorded for younger patients <55 years of age undergoing THA for OA and using either non XLPE or XLPE. There was a fivefold increase in the rate of revision for procedures using non-XLPE after seven years. The 15 year cumulative percent revision of primary THA performed for OA in patients <55 with non XLPE was 17.4% (95% CI 15.5,19.5) and for XLPE was 6.6% (95%CI 5.5,7.8) HR >7 years =5.3, p<0.001. Non-XLPE and XLPE were combined with three different femoral head bearing surfaces: ceramic, metal and ceramicised metal. Within each bearing surface, XLPE had a lower rate of revision than non-XLPE. For the most common head size of 28mm XLPE had a lower rate of revision.

The use of XLPE has resulted in a significant reduction in the rate of revision for younger patients undergoing THA for OA at 15 years. This evidence suggests that longevity of THA is likely to be improved and may enable younger patients to undergo surgery, confident of a reduced need for revision in the long term.